Vitality Biopharma Launches Canadian Subsidiary Focused on Cannabinoid Genetics R&D

Wholly-owned subsidiary to enable access to best available cannabinoid compounds in a federally-compliant manner and facilitate key collaborative research programs LOS ANGELES, CA – (April 5, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide

THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity LOS ANGELES, CA – (March 28, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

2018 Letter to Shareholders

To the Shareholders of Vitality Biopharma, Inc., I wrote to you less than two years ago describing our discovery that a Stevia plant enzyme could be used to create a new class of cannabinoid compounds.  We quickly recognized the value, seeing that these novel molecules, known as cannabosides, might enable targeted delivery and provide therapeutic...

Vitality Biopharma CEO Robert Brooke Provides Shareholder Letter

LOS ANGELES, March 19, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise of a letter issued to Company shareholders.  “As we’re poised to enter a...

Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100

Treatment of pediatric ulcerative colitis will be pursued using targeted cannabinoid therapy that avoids drug psychoactivity LOS ANGELES, CA – ( January 17, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of...

Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC

THC safety record and prior FDA approval propels Vitality’s prodrug as targeted treatment for pediatric IBD without drug psychoactivity LOS ANGELES, CA – (January 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

R&D operations in California registered with DEA to enable production of new class of cannabinoid pharmaceuticals LOS ANGELES, CA – ( November 1, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

Proprietary cannabinoid drug formulations have now been shown to effectively treat preclinical models of Crohn’s disease and ulcerative colitis LOS ANGELES, CA – (Oct 19, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions LOS ANGELES, CA – (October 16, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological...

Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough

R&D team achieves more than 15-fold improvement in biocatalyst production efficiency LOS ANGELES, CA – (October 4, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory...